Vertex Stock Falls After Release Of Phase 2 Results For Suzetrigine Study

Vertex Pharmaceuticals

409.00 CHF -0.23%

• Charts
• News
• Analysen

Kaufen / Verkaufen

(RTTNews) - Shares of Vertex Pharmaceuticals Inc. (VRTX) are falling on Thursday morning after its Phase 2 Study results using placebo showed improved or rather similar results, compared to the investigational compound Suzetrigine for the treatment of painful Lumbosacral radioculopathy.

Placebo showed a reduction of -1.98 in the numeric pain rating scale or NPRS, while Suzetrigine recorded -2.02 on NPRS. The company said the results met primary endpoint with meaningful reduction from baseline in leg pain intensity at the week-12 and was generally tolerated in the study. Adverse events were mild to moderate.

In the pre-market session, shares are currently at $395, down 52.50 points or 11.73 percent, while it closed at $447.50 on Wednesday.

According to Vertex, the study was not designed nor powered for statistical comparison between Suzetrigine and placebo.

The drug candidate is a selective pain signal inhibitor for NaV1.8 relative to other NaV channels.

Secondary and other endpoints were consistent with the study's primary endpoint, the company noted.